BCL2 and lymphoma: Together, we report a synergistic drug combination based on the biological properties of lymphoma, which are ill-prepared for polyploidy and susceptible to combined PLK4 and BCL-2 inhibition to induce and eliminate polyploid cells with negligible toxicity in healthy animals.